CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026
View original at globenewswire.comCLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026 MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermat…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Even patients with active vitiligo disease (where condition is actively spreading) showed a response to afamelanotide therapy in clinical cases
60% confidenceReturning to the AAD for a second year has allowed us to witness a significant maturation in the clinical dialogue surrounding vitiligo
60% confidenceThe overwhelming response to the Pavilion validates CLINUVEL's longstanding focus on melanocortin peptides and reinforces mission to advance clinical programs that reflect life-long needs of patients
60% confidenceClinicians are increasingly identifying practical challenges of long-term treatment dependency and prevalence of relapse upon cessation of JAK inhibitor treatment for vitiligo
60% confidenceCUV105 patient data showed repigmentation following 20 weeks of afamelanotide with adjunct NB-UVB, with patients with darker skin types (Fitzpatrick IV-VI) maintaining pigmentation up to six month follow-up after therapy withdrawal
60% confidenceCLINUVEL's engagement in Denver confirms a growing recognition among the medical community that the next frontier in vitiligo care must prioritise long-term physiological stability and safety beyond immune-suppression
60% confidenceAfamelanotide is not currently approved for vitiligo anywhere in the world
60% confidence